Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT07358234
Phase
EARLY_PHASE1
Status
Enrolling By Invitation

Conditions

  • Eosinophilic Esophagitis (EoE)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to compare Eosinophilic Esophagitis treatments Eohilia with Dupixent in their effects on diameter and scarring of the esophagus.

Key Dates

Start date
Feb 4, 2026
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: budesonide oral suspension (Eohilia)
    2mg twice daily
  • Active Comparator: dupilumab (Dupixent)
    300 mg weekly injection

Primary Outcome Measure

Esophageal diameter [ Time Frame: from enrollment until up to 14 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicScottsdaleArizona85259-
Mayo ClinicRochesterMinnesota55905-

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic· Scottsdale, AZMayo Clinic· Rochester, MN

Related Studies